



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 14/435, 14/475, 14/705; A61K 38/18, 38/17, A61P 3/04, 5/04, C12N 15/12, C12Q 1/68	A1	(11) International Publication Number: WO 00/64931 (43) International Publication Date: 2 November 2000 (02.11.00)
(21) International Application Number: PCT/AU00/00342 (22) International Filing Date: 19 April 2000 (19.04.00) (30) Priority Data: PP 9919 23 April 1999 (23.04.99) AU PQ 6454 24 March 2000 (24.03.00) AU (71) Applicant (for all designated States except US): AUTOGEN PTY LTD [AU/AU]; 210 Kings Way, South Melbourne, Victoria 3205 (AU). (72) Inventors; and (75) Inventors/Applicants (for US only): COLLIER, Greg [AU/AU]; 22 Kestrel Place, Ocean Grove, Victoria 3226 (AU). WALDER, Ken [AU/AU]; 54 Lake Avenue, Ocean Grove, Victoria 3226 (AU). ZIMMET, Paul [AU/AU]; 24 Linlithgow Road, Toorak, Victoria 3142 (AU). (74) Agents: E JOHN L HUGHES et al.; Davies Collison Cave, Level 3, 303 Coronation Drive, Milton, Queensland 4064 (AU).		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: A LIGAND OF THE PROTEIN "BEACON" (57) Abstract The present invention relates generally to a ligand for a protein associated with modulating obesity, diabetes and metabolic energy levels in animals and humans and to genetic sequences encoding the ligand. More particularly, the present invention is directed to a ligand of the protein "beacon" and its homologues. The identification of the ligand molecule permits the development of a range of therapeutic and diagnostic protocols for obesity, diabetes and energy imbalance.		